Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 10/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337210 | 0.87 | PRKCA (0.41) | NR1I2KCNH2PRKCAMMP12SCN9A | |
| SCHEMBL4825577 | 0.86 | PRKCA (0.48) | NR1I2KCNH2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13941188 | 0.86 | NR1I2 (0.57) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936849 | 0.83 | NR1I2 (0.67) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4829897 | 0.83 | NR1I2 (0.67) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14253208 | 0.83 | NR1I2 (0.58) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4823167 | 0.82 | NR1I2 (0.58) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13940449 | 0.82 | NR1I2 (0.53) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936837 | 0.82 | NR1I2 (0.57) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13940888 | 0.82 | NR1I2 (0.64) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | NR1I2 1013/4885KCNH2 4176/4885CYP3A4 500/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | NR1I2 1013/4885KCNH2 4176/4885CYP3A4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.